Prevalence of Metabolic Bone Disease in Tube-Fed Children Receiving Elemental Formula

Ana L. Creo, Lisa M. Epp, Julie A. Buchholtz, Peter Tebben

Research output: Contribution to journalArticle

Abstract

Background: Previous studies suggest normal mineral status in children receiving elemental formula. However, a recent multicenter survey described 51 children who developed hypophosphatemia and bone disease while receiving elemental formula. Our aim is to determine the prevalence of metabolic bone disease in children receiving extensively hydrolyzed or amino acid-based formula. Methods: We established a retrospective cohort using an institutional database of tube-fed children. We defined a "confirmed case" as a child with biochemical and radiographic evidence of bone disease (rickets and/or low-trauma fractures). We defined a "suspected case" as a child who had biochemical evidence and/or radiographic evidence of bone disease but with incomplete data during the review period. Results: A total of 102 tube-fed children receiving elemental or semi-elemental formula were identified. The four elemental and semi-elemental formulas evaluated were Neocate®, EleCare®, Pregestimil®, and Alimentum®. Not all children had complete monitoring data performed during the review period. Of the children receiving Neocate who had monitoring data (46%), 23% developed hypophosphatemia and radiographic abnormalities (fractures or rickets), which resolved with phosphorus supplementation and/or change in the formula brand. Conclusions: We estimate that at least 11% and up to 23% of all tube-fed children receiving Neocate develop metabolic bone disease. Based upon the estimated prevalence, we recommend cautious use of this formula with monitoring for evolving bone disease in this population.

Original languageEnglish (US)
JournalHormone Research in Paediatrics
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Metabolic Bone Diseases
Bone Diseases
Hypophosphatemia
Rickets
Phosphorus
Minerals
Databases
Amino Acids

Keywords

  • Bone mineral disease
  • Elemental formula
  • Neocate
  • Osteopenia
  • Rickets

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Prevalence of Metabolic Bone Disease in Tube-Fed Children Receiving Elemental Formula. / Creo, Ana L.; Epp, Lisa M.; Buchholtz, Julie A.; Tebben, Peter.

In: Hormone Research in Paediatrics, 01.01.2018.

Research output: Contribution to journalArticle

@article{96db75be70ae47e9b245fae8100c47a5,
title = "Prevalence of Metabolic Bone Disease in Tube-Fed Children Receiving Elemental Formula",
abstract = "Background: Previous studies suggest normal mineral status in children receiving elemental formula. However, a recent multicenter survey described 51 children who developed hypophosphatemia and bone disease while receiving elemental formula. Our aim is to determine the prevalence of metabolic bone disease in children receiving extensively hydrolyzed or amino acid-based formula. Methods: We established a retrospective cohort using an institutional database of tube-fed children. We defined a {"}confirmed case{"} as a child with biochemical and radiographic evidence of bone disease (rickets and/or low-trauma fractures). We defined a {"}suspected case{"} as a child who had biochemical evidence and/or radiographic evidence of bone disease but with incomplete data during the review period. Results: A total of 102 tube-fed children receiving elemental or semi-elemental formula were identified. The four elemental and semi-elemental formulas evaluated were Neocate{\circledR}, EleCare{\circledR}, Pregestimil{\circledR}, and Alimentum{\circledR}. Not all children had complete monitoring data performed during the review period. Of the children receiving Neocate who had monitoring data (46{\%}), 23{\%} developed hypophosphatemia and radiographic abnormalities (fractures or rickets), which resolved with phosphorus supplementation and/or change in the formula brand. Conclusions: We estimate that at least 11{\%} and up to 23{\%} of all tube-fed children receiving Neocate develop metabolic bone disease. Based upon the estimated prevalence, we recommend cautious use of this formula with monitoring for evolving bone disease in this population.",
keywords = "Bone mineral disease, Elemental formula, Neocate, Osteopenia, Rickets",
author = "Creo, {Ana L.} and Epp, {Lisa M.} and Buchholtz, {Julie A.} and Peter Tebben",
year = "2018",
month = "1",
day = "1",
doi = "10.1159/000494726",
language = "English (US)",
journal = "Hormone Research in Paediatrics",
issn = "1663-2818",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Prevalence of Metabolic Bone Disease in Tube-Fed Children Receiving Elemental Formula

AU - Creo, Ana L.

AU - Epp, Lisa M.

AU - Buchholtz, Julie A.

AU - Tebben, Peter

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Previous studies suggest normal mineral status in children receiving elemental formula. However, a recent multicenter survey described 51 children who developed hypophosphatemia and bone disease while receiving elemental formula. Our aim is to determine the prevalence of metabolic bone disease in children receiving extensively hydrolyzed or amino acid-based formula. Methods: We established a retrospective cohort using an institutional database of tube-fed children. We defined a "confirmed case" as a child with biochemical and radiographic evidence of bone disease (rickets and/or low-trauma fractures). We defined a "suspected case" as a child who had biochemical evidence and/or radiographic evidence of bone disease but with incomplete data during the review period. Results: A total of 102 tube-fed children receiving elemental or semi-elemental formula were identified. The four elemental and semi-elemental formulas evaluated were Neocate®, EleCare®, Pregestimil®, and Alimentum®. Not all children had complete monitoring data performed during the review period. Of the children receiving Neocate who had monitoring data (46%), 23% developed hypophosphatemia and radiographic abnormalities (fractures or rickets), which resolved with phosphorus supplementation and/or change in the formula brand. Conclusions: We estimate that at least 11% and up to 23% of all tube-fed children receiving Neocate develop metabolic bone disease. Based upon the estimated prevalence, we recommend cautious use of this formula with monitoring for evolving bone disease in this population.

AB - Background: Previous studies suggest normal mineral status in children receiving elemental formula. However, a recent multicenter survey described 51 children who developed hypophosphatemia and bone disease while receiving elemental formula. Our aim is to determine the prevalence of metabolic bone disease in children receiving extensively hydrolyzed or amino acid-based formula. Methods: We established a retrospective cohort using an institutional database of tube-fed children. We defined a "confirmed case" as a child with biochemical and radiographic evidence of bone disease (rickets and/or low-trauma fractures). We defined a "suspected case" as a child who had biochemical evidence and/or radiographic evidence of bone disease but with incomplete data during the review period. Results: A total of 102 tube-fed children receiving elemental or semi-elemental formula were identified. The four elemental and semi-elemental formulas evaluated were Neocate®, EleCare®, Pregestimil®, and Alimentum®. Not all children had complete monitoring data performed during the review period. Of the children receiving Neocate who had monitoring data (46%), 23% developed hypophosphatemia and radiographic abnormalities (fractures or rickets), which resolved with phosphorus supplementation and/or change in the formula brand. Conclusions: We estimate that at least 11% and up to 23% of all tube-fed children receiving Neocate develop metabolic bone disease. Based upon the estimated prevalence, we recommend cautious use of this formula with monitoring for evolving bone disease in this population.

KW - Bone mineral disease

KW - Elemental formula

KW - Neocate

KW - Osteopenia

KW - Rickets

UR - http://www.scopus.com/inward/record.url?scp=85057723968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057723968&partnerID=8YFLogxK

U2 - 10.1159/000494726

DO - 10.1159/000494726

M3 - Article

C2 - 30497080

AN - SCOPUS:85057723968

JO - Hormone Research in Paediatrics

JF - Hormone Research in Paediatrics

SN - 1663-2818

ER -